BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.

Marketing 167

Marketing Regulations Drugs 167

BioPharma Drive: Drug Pricing

AUGUST 25, 2023

market against Biogen’s inflammation-regulating medicine Tysabri. According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S.

FDA Approval 246

FDA Approval FDA Regulations Drugs 246

BioPharma Drive: Drug Pricing

JULY 10, 2024

Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

Regulations 201

Regulations Drugs Production Marketing 201

BioPharma Drive: Drug Pricing

AUGUST 4, 2023

The company said it would withdraw the drug, Adakveo, from the EU market after the European Commission endorsed an earlier EMA recommendation.

Regulations 130

Regulations Marketing Drugs 130

BioPharma Drive: Drug Pricing

APRIL 18, 2025

regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring requirements for Camzyos.

Regulations 175

Regulations FDA Marketing Drugs 175

Advarra

JULY 26, 2022

Even though CBD and cannabis usage has grown, and marketing claims have proliferated regarding potential therapeutic applications, there is still little research on their effects on the human body. The post CBD Research: A Dive into the Regulations of Cannabis Research appeared first on Advarra. Funding Research on Cannabis.

Regulations 97

Regulations Research FDA FDA Approval 97

Fierce BioTech

FEBRUARY 12, 2025

Join us for an exclusive webinar where well guide you through the essential steps of meeting Japans regulations and strict quality requirement. Join us for an exclusive webinar where well guide you through the essential steps of meeting Japans regulations and strict quality requirement. Register now to secure your spot.

Regulations 52

Regulations Marketing Compliance Production 52

Chemical Biology and Drug Design

SEPTEMBER 30, 2023

Abstract Epigenetic regulation of genes through posttranslational regulation of proteins is a well-explored approach for disease treatment, particularly in cancer chemotherapy. Structural classification and regulatory functions of histone deacetylases and their inhibitors.

Regulations 100

Regulations Treatment FDA Disease 100

Drug Patent Watch

DECEMBER 10, 2024

The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 Accelerated Time to Market : By leveraging a connected network of internal experts, integrated CDMOs can help eliminate downtime, optimize processes, and minimize errors, ultimately accelerating time to market.

Drug Development 87

Drug Development Compliance Pharmaceutical Companies Drugs 87

BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge.

Regulations 157

Regulations Marketing 157

ProRelix Research

NOVEMBER 27, 2023

The United States Food and Drug Administration (FDA) has strict regulations regarding pharmacovigilance activities that are a part of post-marketing studies for drugs and medical devices that are required as […] The post FDA Pharmacovigilance Regulations Update appeared first on ProRelix Research.

Regulations 52

Regulations FDA Marketing Research 52

Agency IQ

JANUARY 12, 2024

To kick off 2024, the British device regulator offered its medical device and IVD plans for this year and next, promising public action on the post-market surveillance regulation by mid-2024 and on the core regulations in late 2024 or early 2025. has done.

Regulations 59

Regulations Marketing 59

Cytel

OCTOBER 11, 2023

Moving beyond static evidence development to ensure local market access success; responding to recent changes in governmental drug regulations and the role of automation Written by Grammati Sarri and Radek Wasiak The worldwide drug regulation landscape is rapidly changing.

Marketing 59

Marketing Pharmaceutical Companies Regulations Pharmaceuticals 59

SCIENMAG: Medicine & Health

JUNE 8, 2023

Chilean policies aimed at reining in unhealthy food marketing are succeeding in protecting children from the onslaught of television advertisements (TV ads) for these products, according to new research.

Marketing 66

Marketing Regulations Production Research 66

BioPharma Drive: Drug Pricing

AUGUST 11, 2023

In Europe, however, the biotech is appealing a negative decision from regulators that has for now blocked its path to market there.

Regulations 130

Regulations Marketing Drugs 130

thought leadership

APRIL 14, 2025

Ensuring patient safety and compliance with pharmacovigilance (PV) regulations is a critical responsibility for marketing authorization holders (MAHs). While these countries are centrally located in Europe, they each have distinct national regulations that must be met.

Compliance 52

Compliance Regulations Marketing Production 52

Cytel

MAY 7, 2024

Here we explore the evolution and impact of market exclusivity policies in the EU and US, highlighting their role in fostering innovation and accessibility in rare disease treatment. Market exclusivity for orphan drugs traces back to the early 1980s in the United States, with the landmark Orphan Drug Act of 1983.

Marketing 59

Marketing Production Drugs Disease 59

Drug Patent Watch

DECEMBER 30, 2024

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. New Drug Application (NDA) : Needed for marketing approval of new drugs. Freyr Solutions.

Drug Development 52

Drug Development Clinical Pharmacology Clinical Trials Pharmaceutical Companies 52

Drug Target Review

DECEMBER 20, 2024

These innovations have started to shift industry perceptions, positioning AI as a transformative tool that could alter how drugs are developed, tested, and brought to market. Regulators care a lot about controlling the Type 1 error rate of the clinical trial, Smith notes.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

FDA Law Blog: Biosimilars

MARCH 31, 2024

Gibbs — On March 21, 2024, the House Energy and Commerce held a subcommittee hearing titled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” By Ana Loloei & Jeffrey N. FDA, which was not invited to participate, would surely have concurred.

Regulations 64

Regulations FDA Laboratories Disease 64

Perficient: Drug Development

AUGUST 19, 2024

I have even heard the phrase “Please check the report, I don’t understand the models and hence trust the number” So, in the risk function, while this is a race for data aggregation, structured data, unstructured data, data quality, data granularity, news feeds, market overviews, its also a challenge from an acceptance perspective.

Regulations 109

Regulations Marketing Government Compliance 109

Fierce BioTech

JANUARY 3, 2024

S3 Connected Health Digital health Center for Digital Health Innovative Health Solutions Regulation Resource Type Whitepaper connectedhealth-listing-logo.png Wed, 01/03/2024 - 09:10 Pharma Clinical Data Launches Marketing Special Reports Landing Page Url [link] Byline Sponsored by: S3 Connected Health

Regulations 52

Regulations Marketing 52

Drug Patent Watch

FEBRUARY 12, 2025

However, delays in any of these stages can significantly impact the overall timeline, leading to missed market opportunities and revenue losses. By implementing these strategies, generic drug manufacturers can accelerate their development timelines, improve efficiency, and increase their chances of success in the market.

Drug Development 63

Drug Development Drugs Compliance Regulations 63

Agency IQ

MAY 28, 2024

BY COREY JASEPH, MS, RAC The British medical device regulator just issued its promised framework on international recognition.

International 52

International Regulations Marketing 52

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

(HP&M), a leader in providing legal and regulatory support to the life sciences industries, today announced the appointment of Jeff Grizzel to the newly created position of Chief Marketing Officer (CMO). Grizzel holds a degree in Economics from High Point University and lives in Falls Church, VA.

Marketing 59

Marketing Compliance Science FDA 59

FDA Law Blog: Biosimilars

FEBRUARY 26, 2025

Claud The ongoing DOGE-led reductions to the federal workforce and recent sweeping policy changes have spawned many questions for compliance officers and quality managers in FDA-regulated companies. If a compliance or quality program exists only as bargaining chip to use with regulators, thats not a formula to instill good habits.

Compliance 66

Compliance Regulations FDA Government 66

FDA Law Blog: Biosimilars

JUNE 12, 2024

While that’s not to say that OTC hearing aids aren’t working to address the critical issue of hearing loss, it seems that almost two years is still not enough time to assess market impact, or to show that some of the promises of significant savings for large numbers of consumers have been realized.

FDA 111

FDA Regulations Treatment Licensing 111

PPD

MARCH 11, 2025

Challenge #4: Regulatory and market access hurdles The regulatory and health technology assessment (HTA) pathways for rare disease therapies are complex and vary by region. With the new EU HTA Regulation impacting orphan medicines, navigating these pathways has become even more challenging.

Drug Development 52

Drug Development Clinical Trials Disease Trials 52

Fierce BioTech

APRIL 28, 2025

Accelerating Time-to-Market: Balancing Speed, Compliance, and Operational Excellence jpiatt Mon, 04/28/2025 - 14:42 Tue, 06/24/2025 - 10:00 Resource Type Webinar Promotion Start Thu, 05/01/2025 - 08:30 Promotion End Sat, 11/01/2025 - 08:30 In the highly competitive world of drug development, few things matter more than getting to market first.

Compliance 52

Compliance Marketing Drug Development Regulations 52

Fierce BioTech

OCTOBER 15, 2024

A Pharma Marketers' Roadmap to Data Privacy Compliance : Are You Ready for 2025? swheeler Tue, 10/15/2024 - 19:53 Thu, 11/21/2024 - 13:00 Resource Type Webinar Ben Chapman Duration 60 minutes Join for an insightful webinar on the evolving privacy landscape impacting pharma marketers in 2025.

Compliance 52

Compliance Marketing Regulations 52

thought leadership

SEPTEMBER 30, 2024

If you’re starting to explore marketing your medical device in the European Union (EU) or have a medical device that is currently CE Marked, you’re becoming familiar with the term ‘CER’ or Clinical Evaluation Report. In this post, we’ll explore the fundamentals of the Clinical Evaluation Report (CER). Let’s get started.

Regulations 98

Regulations Marketing Clinical Research Research 98

The Premier Consulting Blog

DECEMBER 28, 2023

1] However, if certain criteria are met, many in vitro diagnostic (IVD) devices are released from IDE regulations. This blog post discusses how device studies are classified and explores scenarios where DVDs qualify for exclusion from IDE regulations. b) Exempt studies that do not require an IDE.

Regulations 52

Regulations FDA Production Compliance 52

Drug Target Review

MAY 14, 2025

The challenges lie in regulated industries where governance frameworks for standard quantitative models dont necessarily apply to LLMs. The challenges lie in regulated industries where governance frameworks for standard quantitative models don’t necessarily apply to LLMs.

Drugs 69

Drugs Science Government Production 69

The Premier Consulting Blog

JANUARY 22, 2024

In the past, medical device developers often chose to bring new products to market in the EU first since obtaining a CE mark was perceived to be faster, less expensive, and more predictable than securing US FDA clearance or approval. The decision of where to launch first requires careful consideration. Degree of novelty. Therapeutic area.

Marketing 52

Marketing Production Regulations FDA 52

Agency IQ

JANUARY 4, 2024

The Swiss regulator, Swissmedic, just announced a reorganization, with a new head of the medicinal product authorization and vigilance sector, but also a new and discrete medical devices surveillance sector. AgencyIQ takes a look at what this could mean for medical device manufacturers. Fill out the form to read the full article.

Marketing 59

Marketing Regulations Production 59

Drug Channels

MARCH 4, 2025

Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. Emerging controversies, challenges, and threats to watch in the industry And much more! As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.

Pharmacy 98

Pharmacy Specialty Pharmacies Marketing Drugs 98

Drug Target Review

APRIL 30, 2025

Faster time-to-market and reduced costs. By integrating AI into the manufacturing process, the developer achieved higher consistency across batches, improved overall product quality, and reduced time-to-market – all critical factors in ensuring patients receive timely and effective treatment. The result?

Therapies 90

Therapies Drugs Clinical Trials Trials 90